Prof. Joaquim Ferreira shares insights from EAN 2025 on the future of Parkinson’s disease care. He discusses realistic timelines for DMTs, the evolving role of gene therapy for genetic subgroups, and the potential of adaptive deep brain stimulation. Prof. Ferreira also highlights the growing importance of optimizing current treatments, interdisciplinary care, and addressing persistent challenges such as gait disturbance, dyskinesia, and cognitive decline.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of upper and lower motor neurons that results in progressive motor impairment. ALS is the most common disease of motor neurons with an annual incidence of approximately 1.7–2.5 per 100,000 people. It is a ...

n this interview, we speak with Dr Anthony Caggiano, Chief Medical Officer and Head of R&D at Cognition Therapeutics, and Lisa Ricciardi, the company’s Chief Executive Officer. They discuss the design and findings of the phase II SHINE trial evaluating zervimesine (CT-1812) in mild to moderate Alzheimer’s disease, including important biomarker and clinical insights presented at recent international conferences. They also reflect on promising data from a study in dementia with Lewy bodies (DLB) and how these results are shaping the company’s next steps.

Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of both upper and lower motor neurons, which ultimately leads to muscle weakness, atrophy, spasticity and contractures.1 ALS typically manifests in the 50–60 years age range, although familial cases may present in ...

Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...

Diabetic striatopathy (DS) is a rare hyperglycaemic condition associated with one or both of the following criteria: (1) acute-onset chorea–ballism (random, flowing and nonsuppressible involuntary movements) and (2) striatal hyperdensity on computed tomography (CT) scan or T1-weighted magnetic resonance imaging (...

Article highlights Multiple screening tests are available to screen patients for cognitive impairment, and the Confusion Assessment Method is a helpful test to screen for delirium in the immediate postoperative period. Medicine reconciliation and identification and removal of potentially inappropriate ...

Explore ground-breaking advancements in the treatment of movement disorders in this insightful interview with Prof. K. Ray Chaudhuri, who shares his key takeaways from the 10th Congress of the European Academy of Neurology meeting in Helsinki. He discusses promising new therapies, personalized care approaches, and significant research on the staging of Parkinson's. Additionally, Prof. Chaudhuri emphasizes the importance of holistic treatment, stepped-care strategies, remote management, and the potential of wearable technology in improving patient outcomes, bringing his wealth of knowledge and insights to touchNEUROLOGY